CRMD vs. TBPH: Which Small-Cap Biotech Stock Is the Better Bet?

CorMedix and Theravance take sharply different routes to small-cap biotech growth - one fueled by sales traction, the other by pipeline promise.

Zacks Investment Research • 13 hours ago

Is the Options Market Predicting a Spike in Theravance Biopharma Stock?

Investors need to pay close attention to TBPH stock based on the movements in the options market lately.

Zacks Investment Research • Jan 28, 2026

Why Theravance Biopharma (TBPH) is a Top Momentum Stock for the Long-Term

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks Investment Research • Jan 23, 2026

Why Theravance Biopharma (TBPH) is a Top Growth Stock for the Long-Term

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks Investment Research • Jan 15, 2026

Here's Why Theravance Biopharma (TBPH) is a Strong Growth Stock

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks Investment Research • Dec 24, 2025

Wall Street Analysts Believe Theravance Bio (TBPH) Could Rally 42.15%: Here's is How to Trade

The mean of analysts' price targets for Theravance Bio (TBPH) points to a 42.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Zacks Investment Research • Dec 22, 2025

Theravance Biopharma, Inc. (TBPH) Discusses Ampreloxetine Phase 3 Program and Unmet Need in Neurogenic Orthostatic Hypotension with Multiple System Atrophy Transcript

Theravance Biopharma, Inc. (TBPH) Discusses Ampreloxetine Phase 3 Program and Unmet Need in Neurogenic Orthostatic Hypotension with Multiple System Atrophy Transcript

Seeking Alpha • Dec 8, 2025

Theravance Biopharma (TBPH) is a Great Momentum Stock: Should You Buy?

Does Theravance Biopharma (TBPH) have what it takes to be a top stock pick for momentum investors? Let's find out.

Zacks Investment Research • Dec 8, 2025

Does Theravance Bio (TBPH) Have the Potential to Rally 30.64% as Wall Street Analysts Expect?

The consensus price target hints at a 30.6% upside potential for Theravance Bio (TBPH). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Zacks Investment Research • Dec 5, 2025

Theravance Biopharma to Host Virtual KOL Investor Event to Review Ampreloxetine Phase 3 Clinical Development Program, Ahead of Topline Data in Q1 2026, on December 8, 2025

DUBLIN , Nov. 20, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) today announced that it will host a virtual key opinion leader (KOL) investor event on Monday, December 8, 2025 at 10:30 AM ET. To register, click here.

PRNewsWire • Nov 20, 2025